Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DICLOFENAC vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
Ankylosing spondylitis,Osteoarthritis,Rheumatoid arthritis,Acute migraine (oral formulation),Mild to moderate acute pain (off-label),Dysmenorrhea (off-label)
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Primarily hepatic via CYP2C9 (major) and CYP3A4 (minor); undergoes glucuronidation. Metabolites include 4'-hydroxydiclofenac, 5-hydroxydiclofenac, and 3'-hydroxydiclofenac.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
>99% bound primarily to serum albumin.
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
0.1-0.2 L/kg (low distribution, reflects high protein binding). Clinical meaning: Limited extravascular distribution; primarily remains in vascular space.
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
Oral immediate-release: ~50% due to extensive first-pass metabolism; Topical: <10% systemic; Ophthalmic: minimal; IV: 100%.
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
GFR >30 m L/min: no adjustment. GFR 15-30 m L/min: use with caution, reduce dose, avoid if possible. GFR <15 m L/min: contraindicated.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
Children ≥1 year: oral 0.5-1 mg/kg/dose twice daily; maximum 3 mg/kg/day or 150 mg/day. Children ≥14 years: same as adult.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
Start at lowest effective dose, e.g., 25-50 mg/day oral; increase cautiously. Avoid NSAIDs in advanced age due to GI and renal risks.
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Diclofenac is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
Cardiovascular risk: increased risk of thrombotic events, hypertension, and heart failure.,Gastrointestinal risk: increased risk of serious GI adverse events including bleeding, ulceration, and perforation.,Renal toxicity: monitor renal function in patients with preexisting renal disease, dehydration, or concomitant nephrotoxic agents.,Hepatic toxicity: elevated liver enzymes; rare cases of severe hepatic reactions.,Anaphylactoid reactions: can occur in patients with or without known NSAID hypersensitivity.,Fluid retention and edema: use with caution in patients with hypertension or heart failure.,Skin reactions: serious cutaneous adverse reactions such as Stevens-Johnson syndrome and DRESS.,Hematologic: prolonged bleeding time; use with caution in patients with coagulation disorders.
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Known hypersensitivity to diclofenac or any component of the formulation,History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in the setting of CABG surgery,Active GI bleeding,Severe uncontrolled heart failure,Advanced renal disease (unless dialysis is ongoing),Third trimester of pregnancy
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
Avoid alcohol as it increases risk of GI bleeding. Take with food or milk to minimize GI irritation. No specific food restrictions, but high-fat meals may delay absorption.
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: Risk of oligohydramnios and fetal renal impairment with prolonged use. Third trimester: Avoid after 30 weeks gestation; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension of the newborn, and oligohydramnios.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
Excreted in breast milk in low amounts; M/P ratio not reported. Use with caution; avoid in breastfeeding mothers with infants with thrombocytopenia or platelet dysfunction. Consider risk of infant renal impairment.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
No dose adjustment recommended for pharmacokinetic changes; however, use at lowest effective dose for shortest duration. Avoid in third trimester due to fetal risks. Consider alternative analgesics in all trimesters.
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
Diclofenac is a potent NSAID with a short half-life, making it suitable for acute pain but requiring frequent dosing. It carries a higher risk of cardiovascular events compared to other NSAIDs; caution in patients with hypertension or heart disease. Enteric-coated formulations may delay onset but reduce GI irritation. Intravenous formulation allows for rapid analgesia but requires monitoring for hypertension and fluid retention. Diclofenac can cause elevation of liver enzymes; monitor LFTs with long-term use. It is available in combination with misoprostol to reduce GI ulcer risk.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting doctor.,Report signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds) or chest pain immediately.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Limit sun exposure and use sunscreen as this drug may increase sun sensitivity.,Do not use in third trimester of pregnancy as it may harm the unborn baby.,Store at room temperature away from moisture and heat.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
"Ximelagatran, an oral direct thrombin inhibitor, increases the risk of bleeding when coadministered with diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The combination potentiates anticoagulant activity through additive inhibition of platelet aggregation and thrombin-mediated coagulation, elevating the risk of gastrointestinal hemorrhage and other serious bleeding events. Patients, particularly those with renal impairment or advanced age, require close monitoring for signs of bleeding."
"Acebutolol, a cardioselective beta-blocker, may attenuate the antihypertensive effect of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac inhibits cyclooxygenase, reducing prostaglandin synthesis, which can lead to sodium retention and increased vascular resistance, thereby counteracting the blood pressure-lowering effects of acebutolol. This interaction may result in diminished blood pressure control, potentially requiring dose adjustments of antihypertensive therapy."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DICLOFENAC vs ACETAMINOPHEN, ASPIRIN AND CAFFEINE, answered by our medical review team.
DICLOFENAC is a NSAID that works by Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DICLOFENAC and ACETAMINOPHEN, ASPIRIN AND CAFFEINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DICLOFENAC is: Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.. The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DICLOFENAC and ACETAMINOPHEN, ASPIRIN AND CAFFEINE. The metabolism of Caffeine can be decreased when combined with Diclofenac. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DICLOFENAC is classified as Category D/X. First trimester: Increased risk of spontaneous abortion and congenital malformations (cardiac defects, gastroschisis) due to prostaglandin synthesis inhibition. Second trimester: R. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.